Literature DB >> 28490211

Adeno-Associated Virus Vectors and Stem Cells: Friends or Foes?

Nolan Brown1,2, Liujiang Song1,2, Nageswara R Kollu1,2, Matthew L Hirsch1,2.   

Abstract

The infusion of healthy stem cells into a patient-termed "stem-cell therapy"-has shown great promise for the treatment of genetic and non-genetic diseases, including mucopolysaccharidosis type 1, Parkinson's disease, multiple sclerosis, numerous immunodeficiency disorders, and aplastic anemia. Stem cells for cell therapy can be collected from the patient (autologous) or collected from another "healthy" individual (allogeneic). The use of allogenic stem cells is accompanied with the potentially fatal risk that the transplanted donor T cells will reject the patient's cells-a process termed "graft-versus-host disease." Therefore, the use of autologous stem cells is preferred, at least from the immunological perspective. However, an obvious drawback is that inherently as "self," they contain the disease mutation. As such, autologous cells for use in cell therapies often require genetic "correction" (i.e., gene addition or editing) prior to cell infusion and therefore the requirement for some form of nucleic acid delivery, which sets the stage for the AAV controversy discussed herein. Despite being the most clinically applied gene delivery context to date, unlike other more concerning integrating and non-integrating vectors such as retroviruses and adenovirus, those based on adeno-associated virus (AAV) have not been employed in the clinic. Furthermore, published data regarding AAV vector transduction of stem cells are inconsistent in regards to vector transduction efficiency, while the pendulum swings far in the other direction with demonstrations of AAV vector-induced toxicity in undifferentiated cells. The variation present in the literature examining the transduction efficiency of AAV vectors in stem cells may be due to numerous factors, including inconsistencies in stem-cell collection, cell culture, vector preparation, and/or transduction conditions. This review summarizes the controversy surrounding AAV vector transduction of stem cells, hopefully setting the stage for future elucidation and eventual therapeutic applications.

Entities:  

Keywords:  AAV vectors; ITR; gene therapy; stem cell; stem cell therapy

Mesh:

Year:  2017        PMID: 28490211      PMCID: PMC5488260          DOI: 10.1089/hum.2017.038

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  172 in total

1.  Integration of adeno-associated virus vectors in CD34+ human hematopoietic progenitor cells after transduction.

Authors:  G Fisher-Adams; K K Wong; G Podsakoff; S J Forman; S Chatterjee
Journal:  Blood       Date:  1996-07-15       Impact factor: 22.113

2.  Adeno-associated virus type 2 modulates the host DNA damage response induced by herpes simplex virus 1 during coinfection.

Authors:  Rebecca Vogel; Michael Seyffert; Regina Strasser; Anna P de Oliveira; Christiane Dresch; Daniel L Glauser; Nelly Jolinon; Anna Salvetti; Matthew D Weitzman; Mathias Ackermann; Cornel Fraefel
Journal:  J Virol       Date:  2011-10-19       Impact factor: 5.103

3.  Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector.

Authors:  X Xiao; J Li; R J Samulski
Journal:  J Virol       Date:  1996-11       Impact factor: 5.103

4.  Origin and termination of adeno-associated virus DNA replication.

Authors:  W W Hauswirth; K I Berns
Journal:  Virology       Date:  1977-05-15       Impact factor: 3.616

5.  Transduction of primitive human marrow and cord blood-derived hematopoietic progenitor cells with adeno-associated virus vectors.

Authors:  S Chatterjee; W Li; C A Wong; G Fisher-Adams; D Lu; M Guha; J A Macer; S J Forman; K K Wong
Journal:  Blood       Date:  1999-03-15       Impact factor: 22.113

6.  Adeno-associated virus and adenovirus coinfection induces a cellular DNA damage and repair response via redundant phosphatidylinositol 3-like kinase pathways.

Authors:  Roy F Collaco; Joyce M Bevington; Vipul Bhrigu; Vivian Kalman-Maltese; James P Trempe
Journal:  Virology       Date:  2009-07-23       Impact factor: 3.616

7.  HSV-I and the cellular DNA damage response.

Authors:  Samantha Smith; Sandra K Weller
Journal:  Future Virol       Date:  2015-04       Impact factor: 1.831

Review 8.  Endocytosis, asymmetric cell division, stem cells and cancer: unus pro omnibus, omnes pro uno.

Authors:  Maximilian Fürthauer; Marcos González-Gaitán
Journal:  Mol Oncol       Date:  2009-06-06       Impact factor: 6.603

9.  Homology-driven genome editing in hematopoietic stem and progenitor cells using ZFN mRNA and AAV6 donors.

Authors:  Jianbin Wang; Colin M Exline; Joshua J DeClercq; G Nicholas Llewellyn; Samuel B Hayward; Patrick Wai-Lun Li; David A Shivak; Richard T Surosky; Philip D Gregory; Michael C Holmes; Paula M Cannon
Journal:  Nat Biotechnol       Date:  2015-11-09       Impact factor: 54.908

10.  High-Efficiency Transduction of Primary Human Hematopoietic Stem/Progenitor Cells by AAV6 Vectors: Strategies for Overcoming Donor-Variation and Implications in Genome Editing.

Authors:  Chen Ling; Kanit Bhukhai; Zifei Yin; Mengqun Tan; Mervin C Yoder; Philippe Leboulch; Emmanuel Payen; Arun Srivastava
Journal:  Sci Rep       Date:  2016-10-19       Impact factor: 4.379

View more
  8 in total

1.  AAV6 Is Superior to Clade F AAVs in Stimulating Homologous Recombination-Based Genome Editing in Human HSPCs.

Authors:  Amanda M Dudek; Matthew H Porteus
Journal:  Mol Ther       Date:  2019-09-12       Impact factor: 11.454

2.  Intrathymic adeno-associated virus gene transfer rapidly restores thymic function and long-term persistence of gene-corrected T cells.

Authors:  Marie Pouzolles; Alice Machado; Mickaël Guilbaud; Magali Irla; Sarah Gailhac; Pierre Barennes; Daniela Cesana; Andrea Calabria; Fabrizio Benedicenti; Arnauld Sergé; Indu Raman; Quan-Zhen Li; Eugenio Montini; David Klatzmann; Oumeya Adjali; Naomi Taylor; Valérie S Zimmermann
Journal:  J Allergy Clin Immunol       Date:  2019-09-09       Impact factor: 10.793

3.  Gene Delivery to Human Limbal Stem Cells Using Viral Vectors.

Authors:  Liujiang Song; Zhenwei Song; Nathaniel J Fry; Laura Conatser; Telmo Llanga; Hua Mei; Tal Kafri; Matthew L Hirsch
Journal:  Hum Gene Ther       Date:  2019-09-25       Impact factor: 5.695

Review 4.  Progress of cationic gene delivery reagents for non-viral vector.

Authors:  Kai Ma; Chun-Liu Mi; Xiang-Xiang Cao; Tian-Yun Wang
Journal:  Appl Microbiol Biotechnol       Date:  2021-01-04       Impact factor: 4.813

5.  Limited potential of AAV-mediated gene therapy in transducing human mesenchymal stem cells for bone repair applications.

Authors:  Sofia Bougioukli; Morgan Chateau; Heidy Morales; Venus Vakhshori; Osamu Sugiyama; Daniel Oakes; Donald Longjohn; Paula Cannon; Jay R Lieberman
Journal:  Gene Ther       Date:  2020-08-17       Impact factor: 5.250

6.  Homologous Recombination-Based Genome Editing by Clade F AAVs Is Inefficient in the Absence of a Targeted DNA Break.

Authors:  Geoffrey L Rogers; Hsu-Yu Chen; Heidy Morales; Paula M Cannon
Journal:  Mol Ther       Date:  2019-09-09       Impact factor: 11.454

Review 7.  Tissue and cell-type-specific transduction using rAAV vectors in lung diseases.

Authors:  Konstantin Kochergin-Nikitsky; Lyubava Belova; Alexander Lavrov; Svetlana Smirnikhina
Journal:  J Mol Med (Berl)       Date:  2021-05-21       Impact factor: 4.599

Review 8.  Harnessing the Natural Biology of Adeno-Associated Virus to Enhance the Efficacy of Cancer Gene Therapy.

Authors:  Jacquelyn J Bower; Liujiang Song; Prabhakar Bastola; Matthew L Hirsch
Journal:  Viruses       Date:  2021-06-23       Impact factor: 5.048

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.